Vitamin D3
Cholecalciferol
Key Benefits
Immune Support
Enhances innate immune response and modulates adaptive immunity, reducing infection risk.
Bone Health
Promotes calcium absorption in the gut and maintains adequate serum calcium and phosphate levels for bone mineralization.
Mood Regulation
Influences neurotransmitter synthesis and may reduce symptoms of seasonal affective disorder and depression.
Hormonal Balance
Supports healthy testosterone levels and endocrine function.
Activation Synergies
Vitamin K2 directs calcium to bones and teeth rather than soft tissues and arteries, preventing arterial calcification while enhancing bone density.
Magnesium is required to convert vitamin D into its active form (calcitriol). Deficiency impairs D3 metabolism and activation.
Curcumin enhances vitamin D receptor expression. Together they provide synergistic anti-inflammatory and immune benefits.
Both support hormonal balance and immune function, working together to enhance mood regulation and stress resilience.
Recommended Dosage
medical_servicesOptimal dosing depends on baseline serum 25(OH)D levels. Consider monitoring blood levels biannually, especially when supplementing above 2000 IU daily.
Deficiency Indicators
- Frequent infections or prolonged illness
- Persistent fatigue and low energy
- Bone pain, muscle weakness, or fractures
- Depression or seasonal mood changes
- Slow wound healing
Scientific Citations
Vitamin D Fact Sheet for Health Professionals
Vitamin D: Evidence and Research Summary
Vitamin D and Immune Function (Aranow, 2011)
Research & Sources
What the evidence says — with links to the original studies
Vitamin D3 (cholecalciferol) is well-supported for one core use: correcting vitamin D deficiency. A large body of peer-reviewed evidence, headlined by the Tripkovic 2012 meta-analysis in the American Journal of Clinical Nutrition, shows D3 raises and sustains serum 25(OH)D more effectively than D2 (ergocalciferol), especially with bolus dosing, making it the preferred supplemental form. Deficiency is common and readily corrected with modest daily doses (RDA 600-800 IU; NIH deficiency threshold <30 nmol/L). Beyond correcting deficiency, the evidence is far more mixed. The landmark VITAL randomized trial (Manson et al., NEJM 2019; ~25,000 largely replete adults, 2000 IU/day) found NO reduction in invasive cancer incidence or major cardiovascular events, though it reported non-significant secondary signals for lower cancer mortality (HR 0.83) and, in a separate VITAL analysis (Hahn, BMJ 2022), a significant ~22% reduction in incident autoimmune disease (HR 0.78). For bone health and falls the picture is genuinely mixed-to-negative in replete community-dwelling adults: the USPSTF concluded evidence does not support routine vitamin D (with or without calcium) to prevent falls or fractures in this group. The strongest disease-prevention signal outside deficiency correction is for acute respiratory infections: Martineau's 2017 BMJ individual-participant-data meta-analysis found a modest protective effect (aOR 0.88) concentrated in daily/weekly (non-bolus) dosing and dramatic benefit in the most deficient (aOR 0.30 for baseline <25 nmol/L). Cofactors magnesium (required for vitamin D activation/metabolism) and vitamin K2 are frequently recommended but rest on mechanistic and observational rather than definitive RCT evidence. Toxicity is rare and occurs only at sustained very high intakes (25(OH)D typically >375 nmol/L / 150 ng/mL); the tolerable upper intake level is 4000 IU/day for most adults.
Supporting Evidence
Foundational D3-vs-D2 meta-analysis. D3 significantly more effective at raising 25(OH)D (weighted mean difference 15.23 nmol/L; P=0.001), with the advantage most pronounced for bolus dosing and attenuated for daily dosing. Open-access via PMC.
25 RCTs, ~11,000 participants. Overall protective effect against acute respiratory infection (adjusted OR 0.88, 95% CI 0.81-0.96), concentrated in daily/weekly non-bolus dosing (aOR 0.81) and strongest in the most deficient (baseline <25 nmol/L: aOR 0.30). Open access.
Pre-specified VITAL ancillary outcome. Vitamin D 2000 IU/day reduced incident confirmed autoimmune disease over ~5 years (HR 0.78, 95% CI 0.61-0.99). Free PMC full text. A positive secondary signal to weigh against VITAL's null primary results.
Reviews magnesium as an essential cofactor for the enzymes that synthesize and metabolize vitamin D; low magnesium status can blunt the response to vitamin D supplementation. Supports the magnesium-cofactor rationale (mechanistic, not RCT-proven).
Authoritative reference for status thresholds (sufficiency >=50 nmol/L; deficiency risk <30 nmol/L), RDA (600-800 IU), tolerable upper intake level (4000 IU/day for adults), and toxicity (25(OH)D typically >375 nmol/L / 150 ng/mL with hypercalcemia). Continuously updated, heavily citation-backed.
Opposing / Critical Views
Definitive primary-prevention null result: ~25,000 mostly replete adults, 2000 IU/day D3 for ~5.3 years. No reduction in invasive cancer incidence (HR 0.96) or major cardiovascular events (HR 0.97). Non-significant lower cancer mortality (HR 0.83, CI crossed 1.0). Undercuts routine supplementation for disease prevention in already-replete adults.
Concluded current evidence is insufficient or does not support routine vitamin D (with or without calcium) to prevent falls or fractures in community-dwelling, non-deficient adults; recommended against low-dose supplementation for this purpose. Reflects the mixed-to-negative bone/falls evidence in replete populations.
Full-text & official documents
Educational summary of published research — not medical advice. Consult a qualified professional before supplementing.
Have You Tried This?
Join our collective laboratory. Share your experience level with this topic and help others gauge the journey.
Based on .
No one has shared yet. Be the first to place a pin on the map.
check_circle You marked yourself as .
Status: In Your Stack Status: Not in Stack